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L E T T E R  T O  T H E  E D I T O R
Subcutaneous immunotherapy using modified Phl p5a‐derived 
peptides efficiently alleviates allergic asthma in mice
To the Editor,
Allergen‐specific immunotherapy (AIT) is a treatment for allergic 
airway disease that induces long‐term tolerance by repeated aller‐
gen injections and induced regulatory T (reg) cells at the expense 
of Th2 cells. Nonetheless, AIT requires large amounts of allergens 
that need to be administered over prolonged periods of time and 
treatment can induce severe side effects. Allergen‐derived peptides, 
encoding the dominant T‐cell epitopes, lack the capacity to bind IgE 
and are a safe alternative. Unfortunately, treatment response to 
peptide AIT is suboptimal for most allergens.1,2 Peptides may have a 
short half‐life after administration and need to be phagocytosed by 
DCs for presentation to T cells to exert their tolerogenic activity. We 
have previously designed a novel strategy to increase uptake and 
presentation of peptides by DCs, while also influencing their tolero‐
genic phenotype.3
Dendritic cells (DCs) express sialic acid‐binding Ig‐like lectins 
(siglecs), which function as endocytic receptors. In mice, sialylation 
of antigens has been shown to instruct DCs to manifest an anti‐
gen‐specific tolerogenic state, enhancing generation of Treg cells 
while reducing the generation of inflammatory T cells.4 Therefore, 
we hypothesize that sialylation of peptides encoding the immu‐
nodominant T‐cell epitopes from the Phleum pratense 5a allergen 
(Phl‐p5a) has the potential to enhance the efficacy of peptide AIT. 
To test our hypothesis, we compared unmodified and sialylated 
Phl‐p5a‐peptides in an experimental grass pollen subcutaneous 
AIT (GP‐SCIT) model,5 to evaluate whether peptide SCIT is effec‐
tive in suppressing allergic airway inflammation and whether the 
use of sialylated peptides leads to increased induction of Tregs and 
enhanced suppression of allergic phenotypes as compared to the 
unmodified peptide SCIT.
We first measured T‐cell activation by DCs loaded with unmod‐
ified or sialylated Phl‐p5a peptides in vitro. Next, GP‐sensitized 
mice received SCIT with unmodified or sialylated Phl‐p5a peptides 
(or control) followed by GP challenges to induce allergic airway 
inflammation. Ear swelling tests were performed, and specific im‐
munoglobulins, airway hyperresponsiveness (AHR), and airway in‐
flammation were measured.6
Two peptides encoding the immunodominant BALB/c T‐cell 
Phl‐p5a epitopes were synthesized, sialylated, and mixed in equi‐
molar ratio for use in the in vitro T‐cell stimulations and in our in 
vivo SCIT model (Figures 1A‐C, S1). We observed that GP‐specific 
T cells showed increased proliferation, higher FoxP3 expression, 
and produced higher TGF‐β1 and reduced IL‐5 levels in response 
to Sia‐peptide‐loaded DCs, as compared to unsialylated controls 
(Figure 1B).
In our in vivo model, (Sia)‐peptide SCIT did not affect the GP‐
specific B‐cell response, in contrast to SCIT using GP extracts 
(Figure S1C). In GP‐sensitized mice, GP‐SCIT and Sia‐peptide SCIT 
resulted in a significantly decreased ear swelling response to GP 
challenges, as compared to controls (Figure S2A). The airway resis‐
tance in response to a dose‐range of methacholine was significantly 
reduced in both GP‐SCIT and (Sia)‐peptide SCIT mice compared to 
controls, with no significant differences between the two treatment 
groups (Figure 1D). Suppression of eosinophilic airway inflammation 
was observed in GP‐SCIT mice compared with Sham‐treated mice in 
both bronchoalveolar lavage fluid (BALF) and lung tissue (Figure 2A). 
Although unmodified peptides failed to significantly reduce eosin‐
ophils in BALF and lung tissue compared with controls, the use of 
sialylated peptides did achieve a significant decrease in eosinophils 
in both BALF and lung tissue compared with sham‐treated mice 
(Figure 2A). We observed a relative suppression of eosinophil num‐
bers by Sia‐peptide SCIT of 7‐fold for BALF and 6‐fold for lung com‐
pared with controls (Figure 2B).
Next, we assessed T‐cell responses in the peptide SCIT‐treated 
mice. Although ILC2s numbers were unaffected by peptide SCIT 
in our model, the number of Th2 (GATA3+) cells was significantly 
decreased in lung tissue after both GP‐SCIT and Sia‐peptide SCIT 
treatment as compared to controls (Figures S2B, 1E). Interestingly, 
FoxP3+ Treg cells were increased in lung tissue only after Sia‐pep‐
tide SCIT, as compared to both controls and mice receiving the un‐
modified peptide (Figure 1E). We observed decreased levels of IL‐5 
in BALF of GP‐SCIT mice, while IL‐10 and IL‐13 were not affected 
(Figure S1E). Moreover, we found significantly decreased levels of 
IL‐4, IL‐13, IL‐33, and IL‐17 in lung tissue from GP‐SCIT and/ or (Sia)‐
peptide SCIT‐treated mice (Figures 2C, S2D).
Last, we evaluated the Th2 activity by measuring cytokine pro‐
duction in GP‐pulsed ex vivo‐cultured lung cell suspensions and ob‐
served a trend toward decreased levels of IL‐5, but not IL‐13, in cells 
from mice treated with GP‐SCIT or Sia‐peptide SCIT (Figures 2D, 
S2C). In addition, levels of IL‐10 were increased in cells from GP‐SCIT 
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F I G U R E  1   A, Outline of (Sia‐) peptides 1 and 2 and co‐cultures of GP‐ or (Sia)‐peptide stimulated BMDCs with CFSE‐labeled CD4+ T 
cells. B, FoxP3+ T cells and CFSELow T cells (both as % of total single living CD3+CD4+ T cells) and levels of TGF‐β1 and IL‐5 pg/mL, n = 12 
(mean ± SEM). C, Outline of the SCIT protocol and treatment groups. D, Airway resistance (R in cmH2O.s/mL) at day 51. E, GATA3
+ and 
FoxP3+ T cells in lung single cells (% live cells) (mean ± SEM). *P < 0.05, **P < 0.01, and ***P < 0.005 compared to unsialylated‐peptide
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and unmodified peptide SCIT mice (Figure 2D). In contrast, TGF‐β1 
levels were only significantly increased in lung cell suspensions from 
mice that had received unmodified peptide SCIT, although differ‐
ences between groups were small (Figure S2C).
In this study, we provide evidence that the use of Phl‐p5a pep‐
tides for SCIT is effective in suppressing asthmatic manifestations 
induced by GP exposure in sensitized mice and that peptide SCIT 
is as effective as GP‐SCIT. Sialylation of the peptides used in SCIT 
resulted in increased T‐cell activation, enhanced numbers of FoxP3+ 
T cells both in vitro and in vivo, and achieved increased suppression 
of Th2 cells and eosinophilic inflammation in lung tissue compared 
to unmodified peptides.
Whereas the GP‐SCIT model is based on the whole GP‐extract 
encompassing all allergens, our peptide SCIT uses two short syn‐
thetic peptides based on the major T‐cell epitopes in Phl p5a,7 which 
might explain why peptide SCIT is not as effective on all parameters 
as the reference GP‐SCIT using crude extracts. It has recently been 
shown that AIT modifies CD4+ T cells in an epitope‐specific manner, 
resulting in depletion of those T‐cell clones that were specifically in‐
creased in allergic patients.8 Therefore, optimal peptide SCIT might 
require peptide sequences from all major GP allergens. Moreover, 
since T‐cell epitopes are dependent on MHC use, a wider variety 
of T‐cell epitopes will be needed to obtain a formulation that can be 
applied in most GP allergic individuals, while keeping the peptides 
as short as possible (20 AA) to prevent IgE cross‐linking and adverse 
events.7 Consequently, the net dosage of each individual peptide in 
the mixture used will be relatively low. We postulate that sialylation 
of the peptides used in such formulations is a valuable approach to 
increase efficiency of peptide SCIT.
In conclusion, the use of sialylated allergen‐derived peptides en‐
coding T‐cell epitopes is a promising approach toward efficient and 
safe AIT treatment regimens.
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